Does the media prefer BEAM or CRSP?

In the previous week, Beam Therapeutics had 6 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 7 mentions for Beam Therapeutics and 1 mentions for CRISPR Therapeutics. Beam Therapeutics' average media sentiment score of 0.92 beat CRISPR Therapeutics' score of 0.59 indicating that Beam Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CRISPR Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BEAM or DNLI?

In the previous week, Beam Therapeutics had 5 more articles in the media than Denali Therapeutics. MarketBeat recorded 7 mentions for Beam Therapeutics and 2 mentions for Denali Therapeutics. Beam Therapeutics' average media sentiment score of 0.92 beat Denali Therapeutics' score of 0.33 indicating that Beam Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Denali Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer NTLA or BEAM?

In the previous week, Beam Therapeutics had 4 more articles in the media than Intellia Therapeutics. MarketBeat recorded 7 mentions for Beam Therapeutics and 3 mentions for Intellia Therapeutics. Beam Therapeutics' average media sentiment score of 0.92 beat Intellia Therapeutics' score of 0.42 indicating that Beam Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intellia Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Beam Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PRME or BEAM?

In the previous week, Beam Therapeutics had 5 more articles in the media than Prime Medicine. MarketBeat recorded 7 mentions for Beam Therapeutics and 2 mentions for Prime Medicine. Beam Therapeutics' average media sentiment score of 0.92 beat Prime Medicine's score of 0.00 indicating that Beam Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prime Medicine 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Beam Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Beam Therapeutics (BEAM) Competitors

$33.20 -2.33 (-6.56%)

Closing price 04:00 PM Eastern

Extended Trading

$33.30 +0.09 (+0.29%)

As of 07:59 PM Eastern

Compare

BEAM vs. CRSP, DNLI, EDIT, NTLA, and PRME

Should you buy Beam Therapeutics stock or one of its competitors? MarketBeat compares Beam Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Beam Therapeutics include CRISPR Therapeutics (CRSP), Denali Therapeutics (DNLI), Editas Medicine (EDIT), Intellia Therapeutics (NTLA), and Prime Medicine (PRME). These companies are all part of the "pharmaceutical products" industry.

How does Beam Therapeutics compare to CRISPR Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and CRISPR Therapeutics (NASDAQ:CRSP) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk.

Beam Therapeutics has a beta of 2.25, meaning that its share price is 125% more volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.74, meaning that its share price is 74% more volatile than the broader market.

99.7% of Beam Therapeutics shares are owned by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 3.8% of Beam Therapeutics shares are owned by insiders. Comparatively, 4.1% of CRISPR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Beam Therapeutics has a net margin of -39.66% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat Beam Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-39.66%	-29.00%	-22.61%
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%

Beam Therapeutics has higher revenue and earnings than CRISPR Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	24.44	-$79.99M	-$0.68	N/A
CRISPR Therapeutics	$3.51M	1,483.57	-$581.60M	-$6.22	N/A

Beam Therapeutics presently has a consensus target price of $46.83, suggesting a potential upside of 41.06%. CRISPR Therapeutics has a consensus target price of $67.78, suggesting a potential upside of 25.54%. Given Beam Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Beam Therapeutics is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71
CRISPR Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.58

In the previous week, Beam Therapeutics had 6 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 7 mentions for Beam Therapeutics and 1 mentions for CRISPR Therapeutics. Beam Therapeutics' average media sentiment score of 0.92 beat CRISPR Therapeutics' score of 0.59 indicating that Beam Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CRISPR Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Beam Therapeutics beats CRISPR Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Beam Therapeutics compare to Denali Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Denali Therapeutics (NASDAQ:DNLI) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends.

Beam Therapeutics presently has a consensus price target of $46.83, indicating a potential upside of 41.06%. Denali Therapeutics has a consensus price target of $34.25, indicating a potential upside of 38.27%. Given Beam Therapeutics' higher possible upside, equities analysts plainly believe Beam Therapeutics is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.81

Beam Therapeutics has a beta of 2.25, meaning that its share price is 125% more volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 1.03, meaning that its share price is 3% more volatile than the broader market.

Denali Therapeutics has a net margin of 0.00% compared to Beam Therapeutics' net margin of -39.66%. Beam Therapeutics' return on equity of -29.00% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-39.66%	-29.00%	-22.61%
Denali Therapeutics	N/A	-52.20%	-43.86%

Beam Therapeutics has higher earnings, but lower revenue than Denali Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	24.44	-$79.99M	-$0.68	N/A
Denali Therapeutics	$330.53M	11.89	-$512.54M	-$2.88	N/A

In the previous week, Beam Therapeutics had 5 more articles in the media than Denali Therapeutics. MarketBeat recorded 7 mentions for Beam Therapeutics and 2 mentions for Denali Therapeutics. Beam Therapeutics' average media sentiment score of 0.92 beat Denali Therapeutics' score of 0.33 indicating that Beam Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Denali Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

99.7% of Beam Therapeutics shares are owned by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are owned by institutional investors. 3.8% of Beam Therapeutics shares are owned by insiders. Comparatively, 12.5% of Denali Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Beam Therapeutics beats Denali Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Beam Therapeutics compare to Editas Medicine?

Editas Medicine (NASDAQ:EDIT) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk and media sentiment.

Beam Therapeutics has higher revenue and earnings than Editas Medicine. Beam Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$40.52M	6.67	-$160.06M	-$1.23	N/A
Beam Therapeutics	$139.74M	24.44	-$79.99M	-$0.68	N/A

Editas Medicine has a beta of 2.16, meaning that its stock price is 116% more volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.25, meaning that its stock price is 125% more volatile than the broader market.

71.9% of Editas Medicine shares are held by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are held by institutional investors. 3.1% of Editas Medicine shares are held by company insiders. Comparatively, 3.8% of Beam Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Beam Therapeutics has a net margin of -39.66% compared to Editas Medicine's net margin of -281.59%. Beam Therapeutics' return on equity of -29.00% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-281.59%	-677.39%	-58.25%
Beam Therapeutics	-39.66%	-29.00%	-22.61%

In the previous week, Beam Therapeutics had 7 more articles in the media than Editas Medicine. MarketBeat recorded 7 mentions for Beam Therapeutics and 0 mentions for Editas Medicine. Beam Therapeutics' average media sentiment score of 0.92 beat Editas Medicine's score of 0.00 indicating that Beam Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Editas Medicine	Neutral
Beam Therapeutics	Positive

Editas Medicine currently has a consensus price target of $5.40, indicating a potential upside of 95.65%. Beam Therapeutics has a consensus price target of $46.83, indicating a potential upside of 41.06%. Given Editas Medicine's higher possible upside, research analysts clearly believe Editas Medicine is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

Beam Therapeutics beats Editas Medicine on 15 of the 17 factors compared between the two stocks.

How does Beam Therapeutics compare to Intellia Therapeutics?

Intellia Therapeutics (NASDAQ:NTLA) and Beam Therapeutics (NASDAQ:BEAM) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends.

Intellia Therapeutics presently has a consensus price target of $20.46, suggesting a potential upside of 34.14%. Beam Therapeutics has a consensus price target of $46.83, suggesting a potential upside of 41.06%. Given Beam Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Beam Therapeutics is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	3 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.35
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71

88.8% of Intellia Therapeutics shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 3.5% of Intellia Therapeutics shares are owned by insiders. Comparatively, 3.8% of Beam Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Beam Therapeutics has a net margin of -39.66% compared to Intellia Therapeutics' net margin of -597.04%. Beam Therapeutics' return on equity of -29.00% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-597.04%	-57.47%	-46.24%
Beam Therapeutics	-39.66%	-29.00%	-22.61%

In the previous week, Beam Therapeutics had 4 more articles in the media than Intellia Therapeutics. MarketBeat recorded 7 mentions for Beam Therapeutics and 3 mentions for Intellia Therapeutics. Beam Therapeutics' average media sentiment score of 0.92 beat Intellia Therapeutics' score of 0.42 indicating that Beam Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intellia Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Beam Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Beam Therapeutics has higher revenue and earnings than Intellia Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$67.67M	31.49	-$412.69M	-$3.54	N/A
Beam Therapeutics	$139.74M	24.44	-$79.99M	-$0.68	N/A

Intellia Therapeutics has a beta of 1.92, indicating that its stock price is 92% more volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.25, indicating that its stock price is 125% more volatile than the broader market.

Summary

Beam Therapeutics beats Intellia Therapeutics on 13 of the 15 factors compared between the two stocks.

How does Beam Therapeutics compare to Prime Medicine?

Prime Medicine (NASDAQ:PRME) and Beam Therapeutics (NASDAQ:BEAM) are both pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Prime Medicine presently has a consensus target price of $7.38, indicating a potential upside of 127.62%. Beam Therapeutics has a consensus target price of $46.83, indicating a potential upside of 41.06%. Given Prime Medicine's stronger consensus rating and higher possible upside, research analysts clearly believe Prime Medicine is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71

Prime Medicine has a beta of 2.31, indicating that its stock price is 131% more volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.25, indicating that its stock price is 125% more volatile than the broader market.

Beam Therapeutics has higher revenue and earnings than Prime Medicine. Beam Therapeutics is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prime Medicine	$4.63M	126.39	-$201.14M	-$1.23	N/A
Beam Therapeutics	$139.74M	24.44	-$79.99M	-$0.68	N/A

Beam Therapeutics has a net margin of -39.66% compared to Prime Medicine's net margin of -4,917.55%. Beam Therapeutics' return on equity of -29.00% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prime Medicine	-4,917.55%	-188.82%	-60.97%
Beam Therapeutics	-39.66%	-29.00%	-22.61%

70.4% of Prime Medicine shares are held by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are held by institutional investors. 16.0% of Prime Medicine shares are held by company insiders. Comparatively, 3.8% of Beam Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Beam Therapeutics had 5 more articles in the media than Prime Medicine. MarketBeat recorded 7 mentions for Beam Therapeutics and 2 mentions for Prime Medicine. Beam Therapeutics' average media sentiment score of 0.92 beat Prime Medicine's score of 0.00 indicating that Beam Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prime Medicine	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Beam Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Beam Therapeutics beats Prime Medicine on 10 of the 16 factors compared between the two stocks.

Get Beam Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BEAM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BEAM vs. The Competition

Export

Metric	Beam Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.66B	$3.45B	$6.45B	$12.39B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-48.82	19.75	24.92	23.98
Price / Sales	24.44	331.30	528.51	109.04
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	2.72	8.29	10.79	6.50
Net Income	-$79.99M	$23.85M	$3.56B	$336.88M
7 Day Performance	7.13%	5.21%	1.67%	-0.22%
1 Month Performance	15.92%	2.19%	0.43%	0.77%
1 Year Performance	98.68%	60.99%	32.84%	31.57%

Beam Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BEAM Beam Therapeutics	3.2842 of 5 stars	$33.20 -6.6%	$46.83 +41.1%	+112.0%	$3.66B	$139.74M	N/A	510
CRSP CRISPR Therapeutics	3.337 of 5 stars	$52.61 +5.6%	$67.78 +28.8%	+22.8%	$4.80B	$3.51M	N/A	460
DNLI Denali Therapeutics	3.1542 of 5 stars	$22.22 +2.6%	$34.25 +54.1%	+73.1%	$3.44B	$330.53M	N/A	430	Analyst Forecast
EDIT Editas Medicine	2.6471 of 5 stars	$2.46 -1.6%	$5.40 +119.5%	+26.1%	$244.77M	$40.52M	N/A	230	Gap Down
NTLA Intellia Therapeutics	3.0931 of 5 stars	$14.92 +23.2%	$20.46 +37.1%	+71.2%	$1.69B	$67.67M	N/A	600	Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BEAM) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Beam Therapeutics (BEAM) Competitors

BEAM vs. CRSP, DNLI, EDIT, NTLA, and PRME

How does Beam Therapeutics compare to CRISPR Therapeutics?

Summary

How does Beam Therapeutics compare to Denali Therapeutics?

Summary

How does Beam Therapeutics compare to Editas Medicine?

Summary

How does Beam Therapeutics compare to Intellia Therapeutics?

Summary

How does Beam Therapeutics compare to Prime Medicine?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BEAM vs. The Competition

Beam Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Beam Therapeutics (BEAM) Competitors

BEAM vs. CRSP, DNLI, EDIT, NTLA, and PRME

How does Beam Therapeutics compare to CRISPR Therapeutics?

Which has more risk and volatility, BEAM or CRSP?

Do insiders and institutionals have more ownership in BEAM or CRSP?

Is BEAM or CRSP more profitable?

Which has better earnings & valuation, BEAM or CRSP?

Do analysts rate BEAM or CRSP?

Does the media prefer BEAM or CRSP?

Summary

How does Beam Therapeutics compare to Denali Therapeutics?

Do analysts recommend BEAM or DNLI?

Which has more risk & volatility, BEAM or DNLI?

Is BEAM or DNLI more profitable?

Which has preferable earnings & valuation, BEAM or DNLI?

Does the media prefer BEAM or DNLI?

Do insiders & institutionals believe in BEAM or DNLI?

Summary

How does Beam Therapeutics compare to Editas Medicine?

Which has higher valuation & earnings, EDIT or BEAM?

Which has more risk & volatility, EDIT or BEAM?

Do institutionals & insiders believe in EDIT or BEAM?

Is EDIT or BEAM more profitable?

Does the media favor EDIT or BEAM?

Do analysts prefer EDIT or BEAM?

Summary

How does Beam Therapeutics compare to Intellia Therapeutics?

Do analysts rate NTLA or BEAM?

Do insiders and institutionals have more ownership in NTLA or BEAM?

Is NTLA or BEAM more profitable?

Does the media prefer NTLA or BEAM?

Which has higher earnings & valuation, NTLA or BEAM?

Which has more volatility and risk, NTLA or BEAM?

Summary

How does Beam Therapeutics compare to Prime Medicine?

Do analysts rate PRME or BEAM?

Which has more risk & volatility, PRME or BEAM?

Which has higher earnings and valuation, PRME or BEAM?

Is PRME or BEAM more profitable?

Do insiders and institutionals hold more shares of PRME or BEAM?

Does the media prefer PRME or BEAM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BEAM vs. The Competition

Beam Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools